Clinical trials: Irinotecan, completed
Metastatic Colorectal Cancer
Safety, Tolerability and Pharmacokinetics of Oral Tablet of Irinotecan in Adult Patients With Solid Tumors
This study evaluates the safety, tolerability and pharmacokinetics of oral administration of irinotecan in adult patients. Oral irinotecan will be administered as monotherapy in a dose escalation trial to establish the Maximal…
- Trial name
- NCT03295084
- Testing
- Irinotecan, Capecitabine
- Where
- Denmark
- Volunteers
- 39 people
- Sponsor
- Dorte Nielsen
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
This is a pilot study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinoma
- Trial name
- NCT03136055
- Testing
- Pembrolizumab, Irinotecan, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of California, San Francisco
Lung Cancer
Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00045604
- Testing
- cisplatin, imatinib mesylate, irinotecan hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasms
Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)
This is a safety and pharmacokinetics study of favezelimab as monotherapy and in combination with pembrolizumab AND favezelimab/pembrolizumab as monotherapy in adults with metastatic solid tumors for which there is no available…
- Trial name
- NCT02720068
- Testing
- Favezelimab, Pembrolizumab, Oxaliplatin
- Volunteers
- 481 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer, Neoplasms, Colorectal
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
This phase 2, randomized, active-controlled, open-label, parallel group, multicenter study will be conducted at up to 18 study centers in the US, Central America, and South America.
- Trial name
- NCT00967616
- Testing
- CS7017, irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)
- Where
- 18 sites in United States, Argentina and 3 more
- Volunteers
- 100 people
- Sponsor
- Daiichi Sankyo
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery
This randomized phase II trial studies how well giving irinotecan hydrochloride with or without alvocidib works in treating patients with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach
- Trial name
- NCT00991952
- Testing
- alvocidib, irinotecan hydrochloride, laboratory biomarker analysis
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Adenocarcinoma of the Pancreas
A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for cancer therapy, namely 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin…
- Trial name
- NAPOLI 3 (NCT04083235)
- Testing
- Irinotecan Liposomal Injection, Oxaliplatin, 5Fluorouracil
- Where
- 200 sites in United States, Australia and 16 more
- Volunteers
- 770 people
- Sponsor
- Ipsen
Metastatic Solid Tumors
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and how safe it is in participants with metastatic cancer (cancer that has spread).
- Trial name
- NCT04319198
- Testing
- Sacituzumab Govitecan-hiy
- Where
- 21 sites in United States, Belgium and 1 more
- Volunteers
- 25 people
- Sponsor
- Gilead Sciences
Colorectal Cancer
Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00628810
- Testing
- bevacizumab, fluorouracil, irinotecan hydrochloride
- Where
- 32 sites in France
- Volunteers
- 86 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Liver Cancer
Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan and flavopiridol, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00087282
- Testing
- alvocidib, irinotecan hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasm, Gastrointestinal
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]
The primary purpose of this trial is to compare the efficacy and safety of DS-8201a and physician's choice treatment in HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma patients who have progressed…
- Trial name
- NCT03329690
- Testing
- DS-8201a, Physician's Choice
- Where
- 66 sites in Japan, South Korea
- Volunteers
- 233 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Extensive Stage Small Cell Lung Cancer
Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer
This phase II trial is studying how well giving cisplatin and irinotecan together with bevacizumab works in treating patients with extensive-stage small cell lung cancer.
- Trial name
- NCT00118235
- Testing
- cisplatin, irinotecan hydrochloride, bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer
RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer receiving chemotherapy may help doctors understand the effect of chemotherapy on biomarkers.
- Trial name
- NCT00559676
- Testing
- capecitabine, fluorouracil, irinotecan hydrochloride
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Centre Hospital Regional Universitaire de Limoges
Colorectal Carcinoma
Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy
The purpose of this study is to determine safety and local tumor control of Embozene TANDEM Microspheres (40um TANDEM) loaded with Irinotecan to treat metastatic colorectal carcinoma (mCRC).
- Trial name
- MIRACLEIII (NCT02694562)
- Testing
- 40um Embozene TANDEM Microspheres
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Boston Scientific Corporation
Colorectal Cancer Metastatic
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
This randomized (2:1), multi-center, placebo-controlled, phase II efficacy study is designed to compare PFS between regorafenib + FOLFIRI chemotherapy (ARM A) versus placebo + FOLFIRI (ARM B) in patients with mCRC previously…
- Trial name
- NCT01298570
- Testing
- Regorafenib (BAY 73-4506), FOLFIRI
- Where
- 24 sites in United States, Ireland
- Volunteers
- 181 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Lung Cancer
Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as amrubicin and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00132054
- Testing
- amrubicin hydrochloride, irinotecan hydrochloride
- Where
- 7 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Japan Multinational Trial Organization
Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
The purpose of this study was to demonstrate superiority of treatment with avelumab plus best supportive care (BSC) versus physician's choice (chosen from a pre-specified list of therapeutic options) plus BSC.
- Trial name
- NCT02625623
- Testing
- Avelumab, Irinotecan, Paclitaxel
- Where
- 75 sites in United States, Australia and 8 more
- Volunteers
- 371 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Colorectal Cancer
Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- OMEGA (NCT00467142)
- Testing
- bevacizumab, fluorouracil, irinotecan hydrochloride
- Where
- France
- Volunteers
- 62 people
- Sponsor
- Institut Bergonié
Metastatic Colorectal Cancer
Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients
Primary Objectives: Aim of this study is to compare the efficacy and safety of two different sequences of chemotherapeutic agents in order to optimize the treatment of patients with metastatic colorectal cancer progressed to a…
- Trial name
- COMETS (NCT01030042)
- Testing
- FOLFOX-4, Irinotecan/Cetuximab
- Where
- 32 sites in Italy
- Volunteers
- 110 people
- Sponsor
- Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Colorectal Cancer
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00027729
- Testing
- etaracizumab
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center